Member Info for CHELSEA7

A very good post wigwammer. good to see you posting here as well.. I rather like this business mosel as we are seeing it with Moditope, that being projects being pursued around Lindy to explore what commercial use it will best be used for, if not many. All adds up to he internal growth of Scancell and optimising human resources of others.

A very exciting phase for Scancell,,. primed for growth and one we all look forward to hearing more about.

Who knows how things could develop here, the potential never doubted, now seeing a business nouse that was doubted by some. Looking forward to this AGM, certainly much to cover for us PIs, and still an SP priced IMHO to build. Hope to be there this year, possibly only eight weeks to wait., and just 12 weeks for the Grand Challenge result. Pivotal times indeed,

3.5% success rate so far. Thats risk.

Thaks boom, makes sense.

OK CHEERS. I would of thought due diligance was done before the deal announcement. Anyway good to see us listed. Night guys

Botski, on those CRUK charts, what does CDP Active mean?

Thanks Ray, that is the important part, something very special is being developed here. Given that what a shame to read todays posts.

Wonder what they call due diligance?

Thanks botski, first time ive seen that,

Really have very little interest in the non-exec director leaving, I rather feel we might just learn soon of a very suitable replacement.

Of more important issues i would really welcome news on SCIB1/2. I rather feel that uncertainty and missing the end H1 deadline is causing more uncertainty than the NED. After taking profit twice in the 30s and knowing the nature of a bio in clinical development i rather doubt Calculas are so unhappy, but if they are wouldn"t it be something if Biontech or any other interested party bought there stake.??

13/08/2018 12:05 17,637 11.272

Thread finished for me. Enjoy your day, i intended to enjoy mine.

Yes it was a rant, of sorts.Surprised you call untruths reasoned views, but then again.

Your post is similar to Agema, making false claims. I know what you said, and you did say that, but not so sure you would have posted it if not for agema.

As I say, it mattered none that his post stating my misinformation was made up, says more about you i"m afraid. Nothing here to paint up as i have said, it will just be very interesting who/if anybody is appointed as a replacement.

That indeed could be the "more than meets the eye", as bermuda said there could be hundreds of reasons, none necessarily bad.

Hotwings, i have got no problem with any post, whether it be positive or negative, but replying as you have to a post deemed fit by untruths to be removed by Admin suggests thats OK with you. Disappointing, i just hope inanaco does not bite, which IMHO is your aim.

Shame, thought you had moved on from that.

"" but there is something we're not being told behind the resignation IMHO.""

Nonsense IMHO, where do you see as the norm reasons behind a non exutive director leaving. Scaremongering.

Hotwings, playing conspiracy theorists. Calculas took a lot of profit at 32p and i think 37p so please like agema don"t play games. His first post today contains falsehoods, i will leave that to Admin.

4 MMs 11-11.7 1 MM

cont/........The fact we see red, however small, on such an RNS makes me want to ask what expectations at this stage the market and investors have. Or is it just that the majority of PIs are looking only at the opportunities afforded by shares offering the quickest buck.

It just saddens me that i have built my holding with the SP as it is. Would have loved to have driven to the share registry to have seen who was behind a few large trades last week, I just have a feeling we shall see plenty more.

Just re reading that RNS again...................................

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that it has embarked on a strategic research collaboration with scientists at the Rheumatology Unit at Karolinska Institutet, Sweden, led by Professors Lars Klareskog and Vivianne Malmström. The collaboration will further explore the scientific and clinical role of citrullinated proteins in the treatment of cancer.

Â

Scancell's Moditope® platform technology overcomes the immune suppression induced by tumours themselves, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. This is achieved by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes, which overcome self-tolerance and destroy tumour cells.

Â

The teams of Professors Klareskog and Malmström have uncovered a central role for citrullinated proteins in the pathogenesis of the autoimmune disease rheumatoid arthritis. Conversely, Scancell has discovered that citrullinated proteins are also targets on cancer cells and this underpins the use of citrullinated peptides in the Company's Moditope® cancer immunotherapy platform.

Â

The groups of Professors Klareskog and Malmström perform world-leading research in the area of rheumatology and their work has been published in a number of leading academic journals, including Nature, Lancet, Arthritis & Rheumatism, Nature Medicine, Nature Genetics and Annual Review of Immunology.

Â

Professor Lindy Durrant, Joint CEO of Scancell and Professor of Cancer Immunotherapy at Nottingham University, commented:

Â

"Our research has previously shown that citrullinated proteins are involved in the control of tumour growth, which led us to the development of the Moditope® platform. The teams of professors Klareskog and Malmström have developed an understanding of the role of citrullinated proteins in the pathogenesis of the autoimmune disease, rheumatoid arthritis. We believe that this strategic collaboration with Karolinska will enhance our joint understanding of the role that citrullination plays in both cancer and rheumatoid arthritis, and will help us develop the Moditope® platform to its full potential."

I really do think that is a great RNS. Hard currency buys us human resources to develop our platforms as much as we can, this agreement with Karolinska has bought two professors and their teams to Moditope. I wonder what the cost of that would be in hard currency?? It is as impressive as the leaders that make up our team in Grand Challenge, surely for a small biotech which we are our development is attracting the leading minds in Oncology. I loathe to say it but i can think of a couple of AIM shares where news like this would cause a rush of excitement.

Just seen your post, as far as im concerned matter closed....................

I notice calculus are invested in Arcis

https://www.calculuscapital.com/investment/arcis-biotechnology/

Kate (that famous scientist) has also resigned from the board of Arcis!

So quite simply, Kate is no longer a director at Calculus, so she has resigned her directorships of companies that calculus have invested in - Scancell and Arcis.